The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET). This dual-therapy targets a pathway ...
MedPage Today on MSN
The latest on emerging therapies for metastatic HR+/HER2- breast cancer
Trastuzumab deruxtecan (T-DXd; Enhertu), is a HER2-targeting ADC that is used in ET-treated HER2-low or HER2-ultralow disease ...
PsiThera, formerly Psivant Therapeutics, raised just over $47 million for oral drugs targeting “diseases long-constrained by ...
Long a quieter, locally focused industry, Japanese pharma giants are increasingly looking to the rest of the world for deals.
In a step forward for bispecific antibodies, study results presented at ASH suggest a Tecvayli-based combination could have ...
Daiichi Sankyo continues to advance its pipeline, offering positive catalysts over the next year. Click here to read why ...
Daiichi Sankyo showcases strength of industry-leading ADC portfolio with latest research updates from five landmark breast cancer trials at SABCS: Tokyo Tuesday, December 9, 2025, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback